Copyright © Inderes 2011 - present. All rights reserved.

Revenio Group

26,54

 

EUR

 

-1,56 %

REG1V

NASDAQ Helsinki

Medical Equipment & Services

Health Care

14.055 følger denne virksomhed
Sammenligne
-1,56%
-8,29%
-0,15%
-2,21%
-17,58%
-1,78%
-34,92%
-8,01%
+1.296,84%

Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand. In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Læs mere
Markedsværdi
708,12 mio. EUR
Aktieomsætning
457,22 t EUR
P/E (adj.) (25e)
29,24
EV/EBIT (adj.) (25e)
21,81
P/B (25e)
5,87
EV/S (25e)
5,95
Udbytteafkast, % (25e)
1,64 %
Coverage
Anbefaling
Akkumulér
Kursmål
30.00 EUR
Opdateret
14.02.2025
Disclaimer
Juha Kinnunen
Juha Kinnunen

Analytiker

Latest research

Seneste analyse

Released: 14.02.2025

Seneste omfattende analyse

Released: 21.01.2025

Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
10.4
2025

Generalforsamling '25

11.4
2025

Årligt udbytte

29.4
2025

Delårsrapport Q1'25

Risiko
Business risk
Valuation risk
Lav
Høj
ViserAlle indholdstyper

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Omfattende analyse af
Juha Kinnunen

Revenio Extensive Report: The future looks bright

Under the iCare brand, Revenio offers excellent tonometers, fundus imaging devices and perimeters. The next step in the company's evolution is to move from being an equipment supplier to providing complete ophthalmic diagnostic solutions, where software and a proprietary AI algorithm are critical.

Revenio Group
Analyse af
Juha Kinnunen

Revenio Q3'24: Slight increase in cost structure

Q3 results were below our expectations, but the main reason for the disappointment was negative FX effects. However, our forecasts for the next few years have been lowered slightly as the company's cost structure has slightly ballooned, but we believe that the increased potential from the Thirona Retina acquisition more than offsets this.

Revenio Group
Value Creators: Revenio
Analyse af
Juha Kinnunen

Value Creators: Revenio

In the Value Creators concept, we highlight companies that have created substantial shareholder value. In this report, we introduce Revenio - a global leader in ophthalmic equipment and software solutions, with a focus on eye care solutions.

Revenio Group
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.